50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): B Cell Receptor Biology and Genetics

Tuesday, December 9, 2008: 7:00 AM-9:00 AM

2001-2003-2014-2016 - West (Moscone Center)

Moderators:

Marc C Levesque, MD, PhD and Nicholas Chiorazzi, MD

7:00 AM

A Different Ontogenesis for CLL Cases Carrying Stereotyped Antigen Receptors: Molecular and Computational Evidence

Nikos Darzentas¹^*, Anastasia Hadzidimitriou¹^*, Fiona Murray²^*, Katerina Hatzi³^*, Par Josefsson⁴^*, Nikolaos Laoutaris⁵^*, Carol Moreno⁶^*, Achilles Anagnostopoulos⁷^*, Jesper Jurlander⁴^*, Athanasios Tsaftaris¹^*, Nicholas Chiorazzi⁸, Chrysoula Belessi⁵, Paolo Ghia⁹, Richard Rosenquist²^*, Frederic Davi¹⁰^* and Kostas Stamatopoulos¹¹^*

¹INA, EKETA, Thessaloniki, Greece
²Dept. of Genetics and Pathology, Rudbeck Lab, Uppsala University, Uppsala, Sweden
³The Feinstein Institute for Medical Research, New York, NY
⁴Dept. of Hematology, Rigshospitalet, Copenhagen, Denmark
⁵Nikea General Hospital, Athens, Greece
⁶Hospital Clinic, IDIBAPS, Barcelona, Spain
⁷G. Papanicolaou Hospital, Thessaloniki, Greece
⁸The Feinstein Inst. for Medical Rsch., Manhasset, NY
⁹Universita Vita-Salute, San Raffaele and Instituto Scientifico San Raffaele, Milan, Italy
¹⁰Hopital Pitie-Salpetriere, Paris, France
¹¹Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

7:15 AM

778

Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

Davide Rossi¹, Valeria Spina¹^*, Michaela Cerri¹^*, Clara Deambrogi¹^*, Lorenzo De Paoli¹^*, Luca Laurenti²^*, Rossana Maffei³^*, Francesco Forconi⁴^*, Vincenzo Canzonieri⁵^*, Francesco Bertoni⁶^*, Maurizio Martini²^*, Silvia Rasi¹^*, Michele Magni⁷^*, Silvia Deaglio⁸^*, Marco Ladetto⁸^*, Antonello Cabras⁷^*, Josep Nomdedeu⁹^*, Caroline Besson¹⁰^*, Roberto Marasca³^*, Luigi Larocca²^*, Valter Gattei⁵^* and Gianluca Gaidano¹^*

¹Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
²Catholic University, Rome, Italy
³University of Modena and Reggio Emilia, Modena, Italy
⁴University of Siena, Siena, Italy
⁵CRO, Aviano, Italy
⁶IOSI, Bellinzona, Switzerland
⁷INT, Milan, Italy
⁸University of Torino, Torino, Italy
⁹Hospital Sant Pau, Barcelona, Spain
¹⁰Hopital Kremlin-Bicetre, Paris, France

7:30 AM

779

The Immunoglobulin Gene Repertoire of Low-Count CLL-Like MBL Is Different from CLL: Diagnostic Considerations and Implications for Clinical Monitoring

Antonis Dagklis¹^*, Claudia Fazi¹^*, Cinzia Sala²^*, Valeria Cantarelli¹^*, Cristina Scielzo¹^*, Roberto Massacane, MD³^*, Daniela Toniolo²^*, Federico Caligaris-Cappio, MD¹, Kostas Stamatopoulos, MD⁴^* and Paolo Ghia, MD, PhD¹

¹Unit and laboratory of Lymphoid Malignancies, Department of Oncology, Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milano, Italy
²Istituto Scientifico San Raffaele, Milano, Italy
³Laboratorio Analisi, A.S.L. 22 - P.O. Novi Ligure, Novi Ligure, Italy
⁴G. Papanicolaou Hospital, Thessaloniki, Greece

7:45 AM

780

Evidence for the Significant Role of Immunoglobulin Light Chains in Antigen Recognition and Selection in Chronic Lymphocytic Leukemia

Anastasia Hadzidimitriou¹^*, Nikos Darzentas¹^*, Fiona Murray²^*, Tanja Smilevska³^*, Eleni Arvaniti⁴^*, Cristina Tresoldi⁵^*, Athanasios Tsaftaris¹^*, Nikolaos Laoutaris⁴^*, Achilles Anagnostopoulos³^*, Frederic Davi⁶^*, Paolo Ghia⁷, Richard Rosenquist², Kostas Stamatopoulos⁸^* and Chrysoula Belessi⁴

¹INA, EKETA, Thessaloniki, Greece
²Dept. of Genetics and Pathology, Rudbeck Lab, Uppsala University, Uppsala, Sweden
³G. Papanicolaou Hospital, Thessaloniki, Greece
⁴Nikea General Hospital, Athens, Greece
⁵HLA Tissue Typing, Immunohematology and Transfusion Medicine Service, Istituto Scientifico San Raffaele, Milan, Italy
⁶Hopital Pitie-Salpetriere, Paris, France
⁷Universita Vita-Salute, San Raffaele and Instituto Scientifico San Raffaele, Milan, Italy
⁸Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

8:00 AM

781

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer¹, Thorsten Zenz¹^*, Dirk Winkler¹^*, Andreas Bühler¹^*, Raymonde Busch²^*, Günther Fingerle-Rowson³^*, Kirsten Fischer³^*, Anna- Maria Fink³^*, Ulrich Jäger⁴^*, Sebastian Böttcher⁵^*, Michael Kneba⁵^*, Michael Wenger⁶^*, Myriam Mendila⁶^*, Michael Hallek³^* and Hartmut Döhner¹^*

¹Internal Medicine III, University of Ulm, Ulm, Germany
²Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
³Dept. of Internal Med. I, Univeristy of Cologne, Cologne, Germany
⁴Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁵2nd Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany
⁶Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland

8:15 AM

782

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

Thorsten Zenz¹^*, Antonio Sarno¹^*, Sonja Häbe¹^*, Tina Denzel¹^*, Julia Mohr¹^*, Dominik Vollmer¹^*, Maria Heuberger¹^*, Dirk Winkler¹^*, Dirk Kienle¹^*, Andreas Bühler¹^*, Sim Truong²^*, Nancy Patten²^*, Michael Hallek³^*, Hartmut Döhner¹ and Stephan Stilgenbauer¹^*

¹University of Ulm, Ulm, Germany
²Roche Molecular Systems, Pleasanton, CA
³Dept. of Internal Med. I, University of Cologne, Cologne, Germany

8:30 AM

783

Epimutation of the Tumor Suppressor Mechanism in 13q14.3 Involves Monoallelic Expression, Non-Coding RNA Genes and Deregulation of NFkB Signalling

Daniel Mertens¹^*, Angela Philippen¹^*, Nupur Bhattacharya¹^*, Cordula Tschuch²^*, Melanie Ruppel²^*, Peter Lichter²^*, Hartmut Doehner¹^* and Stephan Stilgenbauer, MD, PhD¹

¹Internal Medicine III, University of Ulm, Ulm, Germany
²Molecular Genetics, DKFZ, Heidelberg, Germany

8:45 AM

784

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

David Gonzalez, PhD¹^*, Pilar Martinez, MD, PhD²^*, Rachel Wade³^*, Sarah Lorna Hockley, PhD²^*, Vasantha Brito-Babapulle, PhD²^*, David Graham Oscier, MD⁴, Estella Matutes, MD, PhD¹^*, Claire E Dearden¹^*, Sue Richards³^*, Daniel Catovsky, MD, DSc(Med)¹ and Gareth J Morgan, MD, PhD¹

¹Haemato-Oncology, The Royal Marsden Hospital and The Institute of Cancer Research, Surrey, United Kingdom
²Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom
³Ctsu, University of Oxford, Oxford, United Kingdom
⁴Dept. of Hematology, Royal Bournemouth Hospital, Bournemouth

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

641.O4.8 B Cell Receptor Biology and Genetics